Sampling rate and anti-aliasing filters (AAF) affect High Frequency Oscillation (HFO) detection. Sampling rate P2 kHz and AAF P500 Hz should be used to analyze HFOs; lower settings are still useful. Calculating peak HFO frequency is unreliable and highly dependent upon the sampling rate.
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a b s t r a c t
Objective: High Frequency Oscillations (HFOs) are being studied as a biomarker of epilepsy, yet it is unknown how various acquisition parameters at different centers affect detection and analysis of HFOs. This paper specifically quantifies effects of sampling rate (FS) and anti-aliasing filter (AAF) positions on automated HFO detection. Methods: HFOs were detected on intracranial EEG recordings (17 patients) with 5 kHz FS. HFO detection was repeated on downsampled and/or filtered copies of the EEG data, mimicking sampling rates and lowpass filter settings of various acquisition equipment. For each setting, we compared the HFO detection sensitivity, HFO features, and ability to identify the ictal onset zone. Results: The relative sensitivity remained above 80% for either FS P2 kHz or AAF P500 Hz. HFO feature distributions were consistent (AUROC < 0.7) down to 1 kHz FS or 200 Hz AAF. HFO rate successfully identified ictal onset zone over most settings. HFO peak frequency was highly variable under most parameters (Spearman correlation < 0.5). Conclusions: We recommend at least FS P2 kHz and AAF P500 Hz to detect HFOs. Additionally, HFO peak frequency is not robust at any setting: the same HFO event can be variably classified either as a ripple (<200 Hz) or fast ripple (>250 Hz) under different acquisition settings. 
Introduction
High Frequency Oscillations (HFOs) are short, rare events with high power in approximately 80-500 Hz and have been suggested as a biomarker of epilepsy (Bragin et al., 2002; Engel et al., 2009; Wu et al., 2010; Blanco et al., 2011; Park et al., 2012; Haegelen et al., 2013; Kerber et al., 2014) . Research often focuses on HFOs as a biomarker of ictal onset tissue (Cho et al., 2014; Dumpelmann et al., 2014; Malinowska et al., 2014; Okanishi et al., 2014; Gliske et al., 2016) . HFOs have also been considered as a biomarker of a pre-ictal state (Pearce et al., 2013; Malinowska et al., 2014) . Most prior HFO studies require offline processing of high temporal resolution EEG. This processing is either done manually (Urrestarazu et al., 2007) or using automated algorithms (Blanco et al., 2011; Pearce et al., 2013; Gliske et al., 2016) . However, as HFOs have gained considerable favor as a potential clinical biomarker (Jacobs et al., 2012) , the need to implement them in the clinical realm is becoming more pressing. Regardless of the mechanism by which HFOs become available to more clinicians, it is imperative to account for the inevitable differ- 
